Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nucleolar RNA host gene 1 (SNHG1), frequently referred to in clinical research as lncRNA16, is a long non-coding RNA that serves as a critical oncogenic driver in various human malignancies, most notably non-small cell lung cancer (NSCLC). It functions primarily as a competitive endogenous RNA (ceRNA), acting as a 'molecular sponge' for several tumor-suppressive microRNAs, including miR-101-3p, miR-145, and miR-1827. By sequestering these miRNAs, SNHG1 upregulates the expression of oncogenic targets such as SOX9, ZEB1, and MBD3, which in turn promote cell proliferation, inhibit apoptosis, and suppress pyroptosis. In the context of lung cancer, SNHG1 has been shown to drive resistance to platinum-based chemotherapy by inhibiting GSDME-mediated pyroptosis and reducing reactive oxygen species (ROS) accumulation through interactions with mitochondrial proteins like HBB and NDUFAF5. Given its significant overexpression in tumor tissues and its strong correlation with poor clinical outcomes and chemoresistance, SNHG1 is being investigated as both a diagnostic biomarker and a therapeutic target. Preclinical strategies currently focus on RNA interference (e.g., GalNAc-siRNA conjugates) and miRNA-based interventions to restore chemosensitivity and inhibit tumor growth.
Small nucleolar RNA host gene 1 (SNHG1) primarily functions as a competitive endogenous RNA (ceRNA) or 'molecular sponge' that sequesters tumor-suppressive microRNAs (e.g., miR-101-3p, miR-145, miR-1827, miR-326) to upregulate oncogenic downstream targets. It also acts as a scaffold for protein complexes, such as interacting with hemoglobin subunit beta (HBB) and NDUFAF5 in the mitochondria to regulate ROS levels and autophagy.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nucleolar RNA host gene 1 (SNHG1) (SNHG1).